NCT05101356: A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma |
|
|
| Recruiting | 1/2 | 77 | US | Antineoplastic Vaccine, cancer treatment vaccine, Cancer Vaccine, Neoplasm Vaccine, Tumor Vaccine, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Pembrolizumab, KEYTRUDA, MK-3475 | Tianhong Li, National Cancer Institute (NCI), LabyRx Immunologic Therapeutics | Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm | 01/26 | 01/30 | | |
